Solventum Corporation
SOLVHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Solventum Corporation focuses on Medical Instruments & Supplies services and products. Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. The $14.54B market capitalization puts SOLV squarely in large-cap range for its industry. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Market Cap
$14.54B
Beta
0.70
P/E (TTM)
10.45
P/E (Fwd)
11.79
EPS (TTM)
$8.17
EPS (Fwd)
$7.25
ROE
34.0%
ROA
2.7%
Cash
$403.0M
Total Debt
$5.30B
Free CF
$489.0M
52W Change
19.6%
Annual Financials
Cash vs Debt
Where SOLV stands vs its 150-day and 200-day moving averages
As of the September 8, 2026 close, SOLV finished 20.57% above its 150-day moving average ($76.05) and 18.48% above its 200-day moving average ($77.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SOLV overbought or oversold?
At the September 8, 2026 close, SOLV's RSI(14) was 80.2, in overbought territory (above 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $403.0M in cash, though total debt stands at $5.30B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $489.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 34.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $8.13B (2022) to $8.32B (2025).
Solventum Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. No single metric tells the full story. Reviewing SOLV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.